XORTX Therapeutics Inc (XRTX)

XORTX Therapeutics Inc (XRTX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $2.3M; returns 1 day -5.0%, 1 week -25.8%, 1 year -74.4%.

XORTX Therapeutics Inc. (XRTX) is a late-stage clinical pharmaceutical company focused on developing and commercializing therapies for gout and progressive kidney disease. Their lead product, XORLO™ (XRx-026), is an oral oxypurinol formulation targeting allopurinol-intolerant gout, with a planned NDA filing in H1 2026. XORTX estimates a $700 million annual market opportunity for XORLO™.

Groups XRTX belongs to

• Recent Reverse Splits
• Pharmaceuticals
• Canada Companies
• Clinical Stage Biopharma
• Healthcare
• Clinical Stage
• Nephrology
• Rare Diseases
• Biotechnology
• Metabolic Disorders
• Cardiovascular Therapies

XRTX financial model: income statement, cash flow and balance sheet